Puma Biotechnology (NASDAQ:PBYI - Get Free Report) will be posting its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Puma Biotechnology to post earnings of ($0.16) per share for the quarter. Puma Biotechnology has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Persons interested in registering for the company's earnings conference call can do so using this link.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.07). The business had revenue of $72.20 million during the quarter, compared to the consensus estimate of $73.22 million. Puma Biotechnology had a return on equity of 58.21% and a net margin of 9.16%. On average, analysts expect Puma Biotechnology to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Puma Biotechnology Stock Performance
NASDAQ:PBYI traded up $0.05 during mid-day trading on Thursday, hitting $4.88. 231,234 shares of the company traded hands, compared to its average volume of 555,453. Puma Biotechnology has a one year low of $2.13 and a one year high of $7.73. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.23. The firm has a market cap of $235.26 million, a price-to-earnings ratio of 10.61, a price-to-earnings-growth ratio of 2.92 and a beta of 1.28. The stock's fifty day moving average price is $5.59 and its 200-day moving average price is $4.55.
Analysts Set New Price Targets
A number of brokerages recently weighed in on PBYI. HC Wainwright dropped their target price on shares of Puma Biotechnology from $8.00 to $7.00 and set a "buy" rating for the company in a research report on Friday, March 1st. StockNews.com lowered shares of Puma Biotechnology from a "buy" rating to a "hold" rating in a report on Wednesday, April 10th.
Check Out Our Latest Stock Report on PBYI
Puma Biotechnology Company Profile
(
Get Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Further Reading
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
